The following primer, compiled by the MAS team, was designed to educate and empower employees and their families by addressing their most common vaccine-related questions. The information in this primer reflects the evidence as of May 12th, 2021. Please note that the COVID-19 situation and related vaccination guidance is constantly developing. Refer to your municipal, provincial and federal updates for the most up-to-date information.
Here, Medcan’s chief medical officer, Dr. Peter Nord, provides vaccine guidance, addresses concerns about the AstraZeneca vaccine, and discusses how we arrived here and what to expect in the coming weeks.
All vaccines approved by Health Canada are proven to prevent severe illness from COVID-19, resulting in fewer ICU admissions and deaths.
Preventing COVID-19 hospitalizations and deaths will help end this pandemic and vaccination is a massive step forward in this direction. By getting vaccinated, you protect yourself and help your community by reducing the severity of COVID-19 infection.
Much has been reported on COVID-19 vaccine efficacy and effectiveness. But what do they really mean—and what’s the difference between them? In this case, efficacy refers to how well a vaccine works under controlled circumstance, like a clinical trial. Alternatively, effectiveness refers to how well that vaccine works in the real world. To break it down further:
|Covid-19 Vaccine Comparison||Pfizer-BioNTech||Moderna||AstraZeneca-Oxford||Johnson & Johnson|
|Number of Doses||Two doses||Two doses||Two doses||Single dose|
|Minimum Spacing Between Doses||21 days||28 days||28 days||None|
|Vaccine Type||mRNA||mRNA||Adenovirus Vector||Adenovirus Vectore|
|Efficacy rate against severe disease||75-100%||100%||100%||85.4%|
|Disease Prevention in Clinical Trials (Efficacy)||95% efficacy||94% efficacy||76% efficacy||66% efficacy|
|Disease Prevention in Real-World Studies (Effectiveness)||91% effective after first dose according to a recent UK study||70 to 80% effective in preventing infection in England, Quebec, British Columbia and Israel||94% effective in preventing hospitalization (after first dose) in the UK||To be determined|
|Variants of Concern||Likely effective against the B.1.1.7 Variant but likely have a reduced effectiveness against the B.1.351 variant||Likely effective against the B.1.1.7 Variant but likely have a reduced effectiveness against the B.1.351 variant||10.4% efficacy against South African B.1.351 variant||57% effectiveness in South Africa|
|Vaccine Efficacy in Kids||Confirmed for kids aged 12-15||Confirmed for kids aged 16-18||Study has begun for those aged 6-17||Pediatric studies still in planning|
|Storage Requirements||Subzero Temperature||Subzero Temperature||Standard Refrigeration Temperature||Standard Refrigeration Temperature|
|Canadian Doses Ordered||Up to 76 M||44 M||22 M||Up to 38 M|
Vaccines teach your immune system how to fight a specific virus by introducing parts of the invader or weakened/killed pathogen in a way that doesn’t make us ill but instead produces antibodies that can fight that virus. This prepares the immune system to recognize and remember how to fight the virus if exposed in the future. Booster vaccinations stimulate the production of more antibodies and longer lasting memory.
Messenger ribonucleic acid (mRNA) are genetic instructions for our cells to make a harmless piece of the spike protein found on the surface of the COVID-19 virus. The mRNA is encased in a lipid coat so it can enter our cells, which read the instructions like a recipe to create the spike protein. Our bodies create antibodies that can recognize the spike protein and the mRNA is then broken down.Known Vaccines: N/A
COVID-19 Vaccines: Pfizer, Moderna, CureVac
A modified version of a harmless virus (not COVID-19) that delivers spike protein instructions to the cells. In this case, the instructions are DNA instead of mRNA. The vector virus is a type of adenovirus (common cold virus) that has been modified to carry the instructions and to prevent replication.Known Vaccines: Zika, HIV, Ebola
COVID-19 Vaccines: AstraZeneca, Johnson & Johnson, Sputnik V
These vaccines introduce the spike protein rather than just delivering instructions to make it.Known Vaccines: Hepatitis B
COVID-19 Vaccines: Novavax
|Inactivated (attenuated live virus or inactive dead virus)
These vaccines are created by taking the coronavirus and removing its ability to replicate. The spike proteins are left intact, allowing the body to recognize the virus and create antibodies.Known Vaccines: Inactivated (Influenza), Attenuated live virus (MMR)
COVID-19 Vaccines: Sinopharm, Sinovac Biotech, Covaxin
Common vaccine side effects include a sore arm, fatigue and a mild headache. It seems that these symptoms can be worse after the second injection, however, the sore arm should improve within 48-72 hours. One in 10 people will feel muscle aches, chills or a mild fever following vaccination, which is consistent with what is experienced with a normal flu vaccine. While the rate of severe allergic reactions to the mRNA vaccines has been higher than the normal flu vaccine, it remains exceedingly rare, affecting around one in 100,000 people (or 0.001%) in the Pfizer-BioNTech vaccine, for example. Please note that if you are allergic to PEG (polyethylene glycol) or any PEG derivatives like polysorbates, you should speak with your healthcare provider before taking the vaccine. This potential allergen may be found in bowel preparation products for colonoscopy, laxatives, cough syrup, cosmetics, skin products and some food and drinks.
You can find current allergy information and COVID-19 vaccine information on the Canadian Society of Allergy and Clinical Immunology website.
One non-medicinal ingredient in the AstraZeneca vaccine that has the potential to cause type 1 hypersensitivity reactions is polysorbate 80.
Based on continuously evolving research, Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) caused by the AstraZeneca vaccine seems to be rare, occurring in anywhere from one in every 60,000 to one in 100,000. Most of the cases have occurred within 14 days of receiving the AstraZeneca shot, and the majority were in women under the age of 55.
For those under the age of 55 who have been vaccinated with AstraZeneca less than 20 days ago, in the rare event that you develop any symptoms starting four days or more after your vaccination, you should seek immediate medical attention. The list of symptoms is included in NACI’s release, found here.
Thrombosis Canada released a statement strongly recommending all eligible adults receive the AstraZeneca vaccine, including those with a prior blood clot or blood clotting tendency. See full statement here.
MAS recognizes the risk of VITT (vaccine-induced blood clots) may be somewhat higher than originally described as more research has become available. However, at this time due to current wide-spread community infections, the PHAC still recommends that the best vaccine for you, is the first dose available if you are willing to assume that risk.
The vaccine clinical trials did not study the safety nor efficacy in pregnant women nor immunocompromised individuals, which has generated hesitancy and questions.
However, the American Journal of Obstetrics and Gynecology has found that the COVID-19 vaccines do prompt a vigorous immune response in pregnant and breastfeeding women which is passed on to their babies. The Society of Obstetricians and Gynecologists of Canada (SOGC) also released a statement: “Women who are pregnant or breastfeeding should be offered vaccination at any time during pregnancy if they are eligible and no contraindications exist.”
Also, those with an auto-immune disorder should undergo a risk assessment with their primary health care provider or medical specialist to determine that the benefits outweigh the potential risks.
NACI recently recommended implementing an extended four-month interval strategy—but why?
Previous recommended dose separation (21 days) and the new separation recommendation (4 months)
Like influenza, COVID-19 is likely to remain endemic, requiring an updated vaccine annually to address mutations and the new variants of concern. Vaccine manufacturers have confirmed that they can adjust the vaccines in real time to target the new variants of concern, with Moderna already applying for regulatory approvals (clinical trials not required).
The CDC has relaxed guidelines for fully vaccinated individuals, suggesting they do not need to isolate or be tested if exposed to a positive case (unless symptoms develop). As per CDC guidance, vaccinated individuals are able to interact with any number of other vaccinated individuals with unvaccinated family members, however, the Public Health Agency of Canada has yet to issue similar updated guidance.
At the moment, we’re unsure whether vaccinated individuals who contract COVID-19 are still able to transmit the infection to those who are unvaccinated. Current evidence suggests that the viral load and the transmission risk is reduced, but not zero. Overall, vaccinated Individuals must continue to behave, in the community (i.e. work environment), with the same precautions as they did pre-vaccination—wearing masks, physical distancing, and practicing personal hygiene.
These measures will generally remain in place until 75-85% of the population has been fully vaccinated (i.e. received both shots) or has contracted the COVID-19 virus—also known as herd immunity.
To learn more about Medcan’s Medical Advisory Services, send a note to firstname.lastname@example.org.
You can refer to our COVID-19 Vaccine Updates for the latest information on vaccine distribution at Medcan.
Center for Disease Control and Prevention (CDC) – www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html
Center for Effective Practice (CEP)- https://tools.cep.health/tool/covid-19-vaccines/#addressing-patient-questions-about-vaccines
National Advisory Committee on Immunization (NACI) – https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html